QuanterixQTRX
QTRX
About: Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Employees: 136
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
204% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $436K
27% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 44
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
4.22% more ownership
Funds ownership: 86.61% [Q3] → 90.84% (+4.22%) [Q4]
2% more funds holding
Funds holding: 149 [Q3] → 152 (+3) [Q4]
14% less capital invested
Capital invested by funds: $431M [Q3] → $372M (-$58.8M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
156%
upside
Avg. target
$16.50
182%
upside
High target
$18
207%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Sung Nam 0% 1-year accuracy 0 / 2 met price target | 207%upside $18 | Sector Outperform Maintained | 25 Mar 2025 |
Canaccord Genuity Kyle Mikson 34% 1-year accuracy 10 / 29 met price target | 156%upside $15 | Buy Maintained | 18 Mar 2025 |
Financial journalist opinion
Based on 4 articles about QTRX published over the past 30 days
Neutral
Business Wire
1 week ago
Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) and sent a letter to its fellow Quanterix shareholders in connection with its opposition to the Company's proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”).
Neutral
Business Wire
2 weeks ago
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (“Quanterix” or the “Company”) (Nasdaq: QTRX), today issued a statement calling on the Company to explain its most recent purchase agreement for up to $30 million in convertible notes from Akoya Biosciences, Inc. (“Akoya”) (Nasdaq: AKYA). Tikvah's statement follows: “This announcement concerns us for several r.
Neutral
Business Wire
3 weeks ago
Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Biosciences (“Akoya”) (NASDAQ: AKYA) has the ability to sell the Company up to $30 million in convertible notes. Kent Lake.
Neutral
Business Wire
3 weeks ago
Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood spot extraction (DBS) kit as part of their industry-leading Simoa® assay kits at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria. This new extraction kit enables researchers to measure low-concentration biomar.
Neutral
Business Wire
1 month ago
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (Nasdaq: QTRX) (“Quanterix” or the “Company”), today announced that it intends to vote AGAINST the Company's proposed merger with Akoya Biosciences, Inc. (“Akoya”) (Nasdaq: AKYA) at the upcoming Quanterix Special Meeting of shareholders. As a significant investor in the Company since 2018, Tikvah believes the.
Neutral
Seeking Alpha
1 month ago
Quanterix Corporation (QTRX) Q4 2024 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Joshua Young - Head of IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Sung Ji Nam - Scotiabank Operator Thank you for standing by. My name is Kathleen and I will be your conference operator today.
Neutral
Business Wire
1 month ago
Quanterix Releases Financial Results for the Fourth Quarter of 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. “During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained environment,” said Masoud Toloue, Chief Executive Officer of Quanterix. “Our ability to grow in a difficult environm.
Neutral
Business Wire
1 month ago
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of 7.47% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Kent Lake has previously issued a public presentation detailing its opposition to the Company's proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA), and has also nominated three highly qualified, independent candidates for election to the Company's Board of Directors.
Neutral
Business Wire
1 month ago
Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, March 17, 2025, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2024 financial results. Quanterix will issue a press release regarding fourth quarter and full year 2024 financial results prior to the conference call on Monday, March 17, 2025, after the market close.
Neutral
Business Wire
1 month ago
Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) a holder of 7.25% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued a presentation to Quanterix shareholders in connection to Kent Lake's opposition to the Company's proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake's full presentation is available at https://kentlake.s3.us-west-1.amazonaws.com/QTRX-AKYA_KLPRVot.
Charts implemented using Lightweight Charts™